Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04838821
Other study ID # R020-SABI-00268
Secondary ID
Status Recruiting
Phase Phase 2/Phase 3
First received
Last updated
Start date March 29, 2021
Est. completion date September 29, 2021

Study information

Verified date May 2021
Source Caja Costarricense de Seguro Social
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Passive immunotherapy is a therapeutic alternative used in a variety of infectious diseases including COVID-19. Equine polyclonal hyperimmune sera is a source of neutralizing antibodies against SARS-CoV-2 and a therapeutic alternative under investigation in COVID-19 patients. In the previous study NCT04610502 no significant variations were observed regarding efficacy and safety between two different pharmaceutical preparations of equine hyperimmune sera and adequate tolerability was reported with both investigational products. Formulations were produced through repeated immunization with viral recombinant proteins and contain either antibodies against SARS-CoV-2 S1 protein (S type) or a combination of viral proteins that included S1, N (nuclear), E (envelop) and M (membrane) (M type). Another investigation (NCT04494984) found that the administration of a pharmaceutical preparation similar to the S type produced clinical improvement in hospitalized patients with SARS-CoV-2 pneumonia, particularly those with severe disease. Aim: Evaluate the efficacy and safety of three different doses of an anti-SARS-CoV-2 hyperimmune equine serum formulation (S-type) as an addition to the standard therapeutic approach in adult hospitalized patients with a diagnosis of moderate or severe COVID-19, radiological findings consistent with pneumonia and a symptom onset period not exceeding 10 days. A total of 156 patients will be included and randomly divided into four groups, each group will receive a different dose of the investigational drug. On day 1, all participants will receive a single intravenous infusion containing the specified dose according to their assigned group. Clinical assessments, laboratory determinations that include: viral load, antibodies quantification, inflammatory and coagulation markers, cytokines levels as well as standard evaluations will be performed for each patient. Data will be collected for all groups on Days 0 to 7, 14 and 28 or at discharge after completion of treatment. The study will end for each participant on the day of discharge from the hospital.


Recruitment information / eligibility

Status Recruiting
Enrollment 156
Est. completion date September 29, 2021
Est. primary completion date July 29, 2021
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Subjects male or female, aged 18 and over. 2. Acceptance to participate in the study by the signature of the informed consent by the subject or relative (if applicable). 3. SARS-CoV-2 infection confirmed by reverse transcriptase -polymerase chain reaction (RT-PCR). 4. SARS-CoV-2 pneumonia confirmed by chest X-ray. 5. Patients with moderate or severe disease clinical presentation of the disease that require hospitalization. 6. Being within 10 days of the initial COVID-19 related symptoms onset. 7. Admission in the participating center within a 24hour period. 8. Female patients of child-bearing age with a negative pregnancy test. Exclusion Criteria: 1. COVID-19 patients that do not require hospitalization (outpatient setting). 2. Patients who are participating in other therapeutic clinical trials. 3. COVID-19 patients who have received convalescent plasma treatment. 4. Critical disease COVID- 19 patients (respiratory failure, septic shock, and/or multiple organ dysfunction, admission PaO2/FIO2 ratio < 100). 5. Previously snake bitten individuals that received any type of equine hyperimmune serum treatment. 6. History of an allergic reaction due to contact or exposure to horses. 7. Pregnant or breastfeeding women. 8. Patients who, at the investigatorĀ“s discretion, are not likely to comply with study indications and procedures. 9. Patients currently undergoing hemodialysis in a renal support program. 10. Individuals who were previously classified by their treating physicians (prior to the COVID-19 diagnosis), of having an unfavorable prognosis with a short lifespan due to a concomitant disease other than the study disease.

Study Design


Related Conditions & MeSH terms


Intervention

Biological:
Anti SARS-CoV-2 equine hyperimmune serum
All participants in the treatment groups will receive a single intravenous infusion on day 1 containing the specified dose according to their assigned group 12mg/kg, 30 mg/kg or 56mg/kg. Total volume of the infusion is 180ml, to be administered during a time period of at least 1 hour. Study participants will be followed during their hospitalization until they are discharged and on Study Day 28.
placebo
All participants in the placebo group will receive a single intravenous infusion on day 1 containing a specified volume of a saline IV solution preparation. Total volume of the infusion is 180ml, to be administered during a time period of at least 1 hour. Study participants will be followed during their hospitalization until they are discharged and on Study Day 28.

Locations

Country Name City State
Costa Rica Centro Especializado de Atención COVID19 (CEACO) San José
Costa Rica Hospital Dr. Rafael Ángel Calderón Guardia San José
Costa Rica Hospital México San José
Costa Rica Hospital San Juan de Dios San José

Sponsors (3)

Lead Sponsor Collaborator
Caja Costarricense de Seguro Social Ministry of Health Costa Rica, Universidad de Costa Rica

Country where clinical trial is conducted

Costa Rica, 

Outcome

Type Measure Description Time frame Safety issue
Primary Crude Mortality in COVID-19 patients The primary endpoint will be the difference in the proportion of deaths from all causes at 7 and 28 days after the administration of the investigational product between the study groups. day 7 and 28
Secondary Mechanical ventilation assistance (MVA) Change in MVA requirement days between study groups at day 28. day 28
Secondary Hospital stay Change in the overall in-hospital at day 28 stay between study groups. day 28
Secondary Inflammatory markers IL6 Changes in IL-6 levels to be evaluated at days 0, 1, 2, 3, 5, 7, 14 or at time of discharge between study groups. Days 0, 1, 2, 3, 5, 7, and 14 or discharge
Secondary Inflammatory markers CRP Change in CRP levels to be evaluated at days 0, 1, 2, 3, 5, 7, 14 or at time of discharge between study groups. Days 0, 1, 2, 3, 5, 7, and 14 or discharge
Secondary Inflammatory markers Procalcitonin Change in procalcitonin levels to be evaluated at days 0, 1, 2, 3, 5, 7, 14 or at time of discharge between study groups. Days 0, 1, 2, 3, 5, 7, and 14 or discharge
Secondary Inflammatory markers Ferritin Change in ferritin levels to be evaluated at days 0, 1, 2, 3, 5, 7, 14 or at time of discharge between study groups. Days 0, 1, 2, 3, 5, 7, and 14 or discharge
Secondary Thrombotic markers PTT Changes in PTT levels to evaluated at days 0, 1, 2, 3, 5, 7, 14 or at time of discharge between study groups. Days 0, 1, 2, 3, 5, 7, and 14 or discharge
Secondary Thrombotic markers PT Changes in PT levels to evaluated at days 0, 1, 2, 3, 5, 7, 14 or at time of discharge between study groups. Days 0, 1, 2, 3, 5, 7, and 14 or discharge
Secondary Thrombotic markers D Dimer Changes in D Dimer levels to evaluated at days 0, 1, 2, 3, 5, 7, 14 or at time of discharge between study groups. Days 0, 1, 2, 3, 5, 7, and 14 or discharge
Secondary Thrombotic markers Fibrinogen Changes in Fibrinogen levels to evaluated at days 0, 1, 2, 3, 5, 7, 14 or at time of discharge between study groups. Days 0, 1, 2, 3, 5, 7, and 14 or discharge
Secondary SpO2/FIO2 ratio Change in the SpO2/FIO2 ratio to evaluated at days 0, 1, 2, 3, 4, 5, 6, 7 and 14 or at time of discharge between study groups Days 0, 1, 2, 3, 4, 5, 6, 7 and 14 or discharge
Secondary Changes in viral load Change in viral load from baseline to 3 and 7 days after the start of the treatment between study groups Days 0, 3, 7
Secondary Modified Sequential Organ Failure Assessment (mSOFA) Change in the mSOFA score to evaluated at days 0, 1, 2, 3, 5, 7 and 14 or at time of discharge between study groups. Time Frame: Days 0, 1, 2, 3, 5, 7 and 14 or discharge
Secondary WHO 8 point ordinal scale Change in the WHO 8 point ordinal scale of clinical status to evaluated at days 0, 1, 2, 3, 4, 5, 6, 7, 14 and 28 or at time of discharge between study groups. Days 0, 1, 2, 3, 4, 5, 6, 7, 14 and 28 or discharge
Secondary Anti SARS-CoV-2 antibodies Change in the anti SARS-CoV-2 antibodies titer levels to evaluated at days 0, 1, 2, 3, 5, 7 and 14 or at time of discharge between study groups. Days 0, 1, 2, 3, 5, 7 and 14 or discharge
Secondary Adverse events Incidence of adverse events as measured by CTCAE v. 5.0 at day 28 between study groups. day 28
See also
  Status Clinical Trial Phase
Completed NCT05047692 - Safety and Immunogenicity Study of AdCLD-CoV19-1: A COVID-19 Preventive Vaccine in Healthy Volunteers Phase 1
Recruiting NCT04395768 - International ALLIANCE Study of Therapies to Prevent Progression of COVID-19 Phase 2
Completed NCT04508777 - COVID SAFE: COVID-19 Screening Assessment for Exposure
Terminated NCT04555096 - A Trial of GC4419 in Patients With Critical Illness Due to COVID-19 Phase 2
Completed NCT04506268 - COVID-19 SAFE Enrollment N/A
Completed NCT04961541 - Evaluation of the Safety and Immunogenicity of Influenza and COVID-19 Combination Vaccine Phase 1/Phase 2
Active, not recruiting NCT04546737 - Study of Morphological, Spectral and Metabolic Manifestations of Neurological Complications in Covid-19 Patients N/A
Terminated NCT04581915 - PHRU CoV01 A Trial of Triazavirin (TZV) for the Treatment of Mild-moderate COVID-19 Phase 2/Phase 3
Not yet recruiting NCT04543006 - Persistence of Neutralizing Antibodies 6 and 12 Months After a Covid-19 N/A
Completed NCT04494646 - BARCONA: A Study of Effects of Bardoxolone Methyl in Participants With SARS-Corona Virus-2 (COVID-19) Phase 2
Completed NCT04532294 - Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2/COVID-19) Neutralizing Antibody in Healthy Participants Phase 1
Terminated NCT04542993 - Can SARS-CoV-2 Viral Load and COVID-19 Disease Severity be Reduced by Resveratrol-assisted Zinc Therapy Phase 2
Completed NCT04507867 - Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III N/A
Not yet recruiting NCT04527211 - Effectiveness and Safety of Ivermectin for the Prevention of Covid-19 Infection in Colombian Health Personnel Phase 3
Completed NCT04387292 - Ocular Sequelae of Patients Hospitalized for Respiratory Failure During the COVID-19 Epidemic N/A
Completed NCT04537663 - Prevention Of Respiratory Tract Infection And Covid-19 Through BCG Vaccination In Vulnerable Older Adults Phase 4
Completed NCT04979858 - Reducing Spread of COVID-19 in a University Community Setting: Role of a Low-Cost Reusable Form-Fitting Fabric Mask N/A
Not yet recruiting NCT05038449 - Study to Evaluate the Efficacy and Safety of Colchicine Tablets in Patients With COVID-19 N/A
Completed NCT04610502 - Efficacy and Safety of Two Hyperimmune Equine Anti Sars-CoV-2 Serum in COVID-19 Patients Phase 2
Active, not recruiting NCT06042855 - ACTIV-6: COVID-19 Study of Repurposed Medications - Arm G (Metformin) Phase 3